Sinopharm Group Co Ltd
01099: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$85.50 | Nqlkpwy | Pkktqhcmg |
Sinopharm: The Market Leader in China's Medical Distribution
Business Strategy and Outlook
Sinopharm is well positioned in the fast-growing and rapidly consolidating Chinese drug distribution industry. Like most healthcare sectors in China, drug distribution has grown faster than GDP, and will continue to grow quickly due to aging demographics, increased urbanization, a larger middle class, and rising disease rates.